Why newborn screening matters for Duchenne muscular dystrophy

Newborn screening has transformed the outlook for several rare genetic diseases by enabling diagnosis before symptoms appear. Following the announcement that all newborns in England will be screened for spinal muscular atrophy (SMA) from 2027, clinicians and patient advocates are calling for broader discussions about extending newborn screening to include other serious genetic conditions, including Duchenne muscular dystrophy (DMD).

Although newborn screening for DMD is not currently part of routine screening programmes in the UK or most European countries, increasing treatment options and a greater understanding of the benefits of early diagnosis have renewed interest in its potential role.

 

Why early diagnosis matters

Duchenne muscular dystrophy affects approximately 1 in 3,500–5,000 live male births worldwide. Despite advances in genetic testing, many children still experience a prolonged diagnostic journey, often involving multiple healthcare appointments before receiving a definitive diagnosis.

Earlier identification through newborn screening could:

  • Reduce the diagnostic delay experienced by many families.
  • Provide earlier access to specialist neuromuscular care.
  • Enable genetic counselling and informed family planning.
  • Allow timely enrolment into clinical trials where appropriate.
  • Ensure children receive supportive interventions during the earliest stages of development.

As more disease-modifying therapies become available, diagnosing children before significant muscle damage occurs may become increasingly important for maximising treatment benefit.

Implications for brain health

While Duchenne muscular dystrophy is widely recognised as a neuromuscular disorder, dystrophin is also expressed in the brain. Many boys with DMD experience neurodevelopmental and neurobehavioural differences, including learning difficulties, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), anxiety and language delays.

These features often emerge during early childhood, sometimes before obvious muscle weakness develops. Earlier diagnosis through newborn screening could therefore support:

  • Earlier developmental monitoring.
  • Timely neuropsychological assessment.
  • Access to speech and language therapy.
  • Educational support.
  • Behavioural and psychological interventions.

This proactive approach has the potential to improve educational, social and behavioural outcomes while supporting families during the critical early years of development.

Current landscape

Several pilot newborn screening programmes for DMD have been undertaken internationally, demonstrating that screening is technically feasible. Discussions continue regarding the balance between the benefits of earlier diagnosis, healthcare resources, treatment availability and long-term follow-up.

The recent introduction of newborn screening for SMA in England has renewed debate about whether similar approaches should be considered for DMD as therapeutic options continue to expand. Patient organisations and researchers have highlighted that earlier diagnosis is valuable not only because of treatment opportunities, but also because it enables families to access specialist support, make informed decisions and better prepare for the future.

Why this matters to the BIND community

The BIND Association is committed to improving understanding of the brain involvement associated with Duchenne and Becker muscular dystrophies.

Earlier diagnosis provides an opportunity to integrate neurodevelopmental assessment into routine care from infancy, ensuring cognitive, behavioural and emotional needs are recognised alongside physical health. This aligns with BIND’s mission to promote multidisciplinary research and improve quality of life for individuals living with dystrophinopathies.

As newborn screening policies continue to evolve internationally, consideration of brain health should form an important part of future discussions surrounding early diagnosis and clinical care.

Take home messages

  • Newborn screening has the potential to reduce delays in diagnosing DMD
  • Earlier diagnosis may improve access to specialist care, emerging therapies and clinical trials
  • Early identification also creates opportunities to monitor and support neurodevelopment from infancy
  • As treatment options continue to advance, newborn screening is likely to remain an important topic for clinicians, researchers, policymakers and patient organisations

Further Reading

Hoskin J. Broaden newborn screening programmes. The Guardian. Published 21 July 2026.